Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samrat Pharmachem's Total Assets for the quarter that ended in Mar. 2026 was ₹1,244 Mil.
Warning Sign:
If a company builds assets at 17.2% a year, faster than its revenue growth rate of 9.2% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Samrat Pharmachem's average Total Assets Growth Rate was -2.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 4.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 17.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 17.20% per year.
During the past 13 years, Samrat Pharmachem's highest 3-Year average Total Assets Growth Rate was 37.70%. The lowest was -6.20%. And the median was 18.20%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Samrat Pharmachem's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Samrat Pharmachem Total Assets Related Terms
Samrat Pharmachem Total Assets Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Samrat Pharmachem's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samrat Pharmachem (BOM:530125) has a Total Assets of ₹1,244 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Samrat Pharmachem and its competitors.
Is Samrat Pharmachem's Total Assets too high?
Samrat Pharmachem's current Total Assets is ₹1,244 Mil. Overall, Samrat Pharmachem has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Total Assets compare to DOW?
Samrat Pharmachem's Total Assets of ₹1,244 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Chemicals company?
A good Total Assets depends on the Chemicals industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Samrat Pharmachem and its competitors. Samrat Pharmachem's current Total Assets is ₹1,244 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.79, compared to a current price of ₹251.95 — trading 30.6% below its estimated fair value. The current Total Assets is ₹1,244 Mil. Samrat Pharmachem's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Total Assets is ₹1,244 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹251.95 is trading 30.6% below its estimated GF Value™ of ₹362.79.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
Total Assets: ₹1,244 Mil
GF Value™: ₹362.79 vs. price of ₹251.95 (30.6% below fair value)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
63GF Score
Get the complete analysis for BOM:530125
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
